So is this merely using our exosome technology to aid UQ in developing their own ovarian cancer screening assay?
Is it using our subB2m markers, as we are still developing that assay if I understand correctly (the results of which caused us to rocket to $4). Or is this a completely different assay, which means we are helping develop a competitor or we have abandoned our previous assay?
What role do we take in ownership? What piece of the funding do we get?
These are legit questions, I read over the agreement pretty quickly but this honestly raises more questions for me than it answers.
Ann: INOVIQ & UQ Collaborate on Exosome-based Ovarian Cancer Test, page-11
Add IIQ (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
43.5¢ |
Change
0.000(0.00%) |
Mkt cap ! $48.51M | |||
| Open | High | Low | Value | Volume |
| 43.5¢ | 43.5¢ | 43.0¢ | $14.65K | 33.71K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 9690 | 43.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 44.0¢ | 7500 | 1 |
View Market Depth
| Last trade - 14.03pm 06/11/2024 (20 minute delay) ? |
| IIQ (ASX) Chart |